Fast Track for Innovative and Orphan Products: Incentive Direction and Practical Thresholds

1. Key takeaways

Federal Decree-Law No. 38/2024 establishes a fast track for innovative medical products of therapeutic importance, defines Innovative and Orphan in Article 1, and opens the conditional authorization route of Articles 8 to 10 to products related to rare diseases. Our judgment is that the direction is clear while the threshold is not yet fixed. What the fast track changes is the rhythm of review, not the statutory conditions of Article 6(1)(a) through (h); with the Executive Regulations under the Decree-Law not yet all issued, the details of the recognition criteria and the application materials should be locked down through written confirmation from EDE.

• The Decree-Law establishes a fast track for innovative medical products of therapeutic importance and defines Innovative and Orphan in Article 1.
• Products related to rare diseases can use the conditional marketing authorization route of Articles 8 to 10, whose validity period is 1 year.
• Article 6(1)(h) reserves further conditions for the Executive Regulations, so the detail of the incentive mechanisms remains an open matter.
• The fast track changes the pace of review, not the substantive conditions; applicant eligibility, the quality system, the GMP certificate and labelling all still apply.

2. Legal basis

The fast track rests on the definitions in Article 1 of Federal Decree-Law No. 38/2024, on the conditional authorization route in Articles 8 to 10, and on the reserved conditions in Article 6, summarised below.

3. Expert insights

Insight 1: The definitions stand in law, but the recognition waits on procedure. Article 1 gives definitions of Innovative and Orphan, which shows the legislature intended to single this class of product out. But who makes the recognition, what corroborating materials are needed, and how the fast element shows up in the review sequence all sit in the Executive Regulations and in the service design of EDE. Our approach is to write the definitions article into the filing explanation as the legal basis for the fast-track claim, while obtaining written answers on the uncertain elements, rather than preparing an entire dossier first on our own interpretation.

Insight 2: The fast track does not waive the conditions of Article 6. Applicant eligibility, the quality and traceability system, the GMP certificate, and labelling and instructions for use: innovative products must satisfy each of these item by item, exactly as any other product. Our judgment is that what is genuinely saved is the time spent queuing and travelling through round-trips, not the evidence itself. Companies that treat the fast track as a halving of the conditions tend to be rejected on applicant eligibility under item (a) and the GMP certificate under item (f), and end up slower than the regular route.

Insight 3: Orphan products require a long-horizon calculation. The market for a rare disease product is small, yet the vigilance obligations of Article 21(6), the lead responsible entity and whole-lifecycle arrangements of Article 22, and the requirement that every appointed entity actually carry out imports in the year concerned all apply without exception. Our advice is to calculate the annual cost of the vigilance system, the local entity and inventory turnover before committing to the filing, and then decide whether to invest. The 1-year validity of the conditional authorization also adds an annual administrative burden of renewal and conversion.

4. Practical recommendations

• Match the product against the definitions in Article 1, and state the legal basis for the innovative or rare disease attribute in the filing explanation.
• Obtain written confirmation from EDE on the recognition criteria, the application materials and the review rhythm, and use it as the basis for scheduling.
• Prepare the evidence for Article 6(1)(a) through (h) exactly as for the regular route, treating the fast track as a pacing variable rather than a reduction of conditions.
• For orphan products, estimate the annual running cost of vigilance and the local entity in advance and fold it into the commercial feasibility assessment.
• Design the evidence completion and conversion plan for the conditional authorization around the 1-year validity period, avoiding gaps between certificates.
• Organise reference-country evidence in parallel: recognition conclusions on comparable innovative or orphan products issued by the EMA, FDA and similar authorities can support the item (c) assessment.

5. Verification checklist

• □ The product has been matched against the Article 1 definitions, with the basis for the innovative or orphan attribute stated in writing.
• □ A written reply from EDE or an official acceptance response has been obtained on the recognition criteria and the material list.
• □ Evidence for Article 6(1)(a) through (h) is complete to the regular standard, with no gaps caused by taking the fast track.
• □ The vigilance system and the Article 22 lead responsible entity arrangements are settled, and the annual running cost has been estimated.
• □ The evidence completion plan for the conditional authorization matches the 1-year validity period.
• □ Recognition conclusions on comparable products from reference authorities are included in the item (c) evidence chain.

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages MOHAP registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com